Astrana Health (NASDAQ:ASTH) Sets New 52-Week Low on Analyst Downgrade

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price reached a new 52-week low during trading on Monday after Truist Financial lowered their price target on the stock from $59.00 to $50.00. Truist Financial currently has a buy rating on the stock. Astrana Health traded as low as $29.08 and last traded at $29.42, with a volume of 13470 shares. The stock had previously closed at $29.48.

Several other equities research analysts also recently weighed in on ASTH. Macquarie raised Astrana Health to a “hold” rating in a research report on Monday, December 16th. KeyCorp assumed coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating for the company. Robert W. Baird boosted their price target on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. TD Cowen started coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 target price for the company. Finally, BTIG Research raised their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.67.

Institutional Trading of Astrana Health

A number of institutional investors have recently bought and sold shares of ASTH. State Street Corp acquired a new position in Astrana Health during the third quarter worth about $91,966,000. Geode Capital Management LLC purchased a new position in shares of Astrana Health during the 3rd quarter worth approximately $58,995,000. FMR LLC acquired a new position in shares of Astrana Health during the 3rd quarter worth approximately $48,413,000. SteelPeak Wealth LLC purchased a new stake in Astrana Health in the 3rd quarter valued at approximately $39,398,000. Finally, Loomis Sayles & Co. L P acquired a new stake in Astrana Health during the 3rd quarter valued at $30,251,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Stock Up 2.7 %

The company has a market cap of $1.70 billion, a PE ratio of 23.29, a P/E/G ratio of 1.80 and a beta of 1.20. The firm has a 50-day simple moving average of $39.55 and a two-hundred day simple moving average of $47.05. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The business had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same quarter in the prior year, the firm posted $0.47 earnings per share. Research analysts anticipate that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.